Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 112,013

Document Document Title
WO/2016/008966A1
The present invention relates to methods for treating neuromuscular junction-related diseases. In particular, the present invention relates to a method of treating a neuromuscular junction-related disease in a subject in need thereof com...  
WO/2016/009065A3
The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R" does not exist when Q is O; R' independently represent a hydrogen ...  
WO/2016/009341A1
The present invention provides thioredoxin (TRX) mimetic prodrugs, more particularly, derivatives or analogues of the amino acid sequence Cys-Pro-Cys or A1 -Cys- A2 -Pro-A3 -Cys-A4 wherein A1 to A4 each independently is either absent or ...  
WO/2016/008650A1
The present invention relates to the use of a combination of valerian root extract and lavender oil for the treatment of sleep disorders, and to a combination drug comprising valerian root extract and lavender oil.  
WO/2016/009297A1
The present invention provides, in part, compounds of Formula I: (I) N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and co...  
WO/2016/009430A1
An agent that reduces type I IFN activity at the choroid plexus or within the CNS for use in treating a disease, disorder, condition or injury of the CNS is provided.  
WO/2016/009021A1
The present invention relates to a dosage form which comprises two units A and B the composition of which is adapted to the circadian rhythm such that the dosage form can contribute to a perceptible increase in well-being. The dosage for...  
WO/2016/011088A2
The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueou...  
WO/2016/008047A1
Pharmaceutical compositions and methods for the treatment or prophylaxis of Amyloid beta-related disorders such as Alzheimer's disease in a subject are provided by vaccination using a cyclic peptide or antibody to the SNK epitope in the ...  
WO/2016/011037A1
The unique polymeric OGF and enkephalin peptide conjugates with large size polymer attached at the C-terminus through hydrolysable linkage enhancing therapeutic properties of OGF and enkephalin peptides.  
WO/2016/009066A1
The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition comprising said compound ...  
WO/2016/010108A1
A compound represented by formula (I) [in the formula: (1) represents (2), (3), etc.; R2a represents optionally substituted alkyl, etc.; R2b, R3a, R3b, R4a, R4b, R5a and R5b independently represent a hydrogen atom, etc.; and R1 represent...  
WO/2016/011270A2  
WO/2016/010092A1
Provided are: a compound that is useful as an amyloid oxidation catalyst which can be applied inside a living body and can be applied not only to Aβ peptides but also to other amyloids; and an amyloid-related preventive or therapeutic d...  
WO/2016/007729A1
Provided herein are drug products comprising a combination of an opioid receptor agonist and an opioid receptor agonists, including co-packaged drug products comprising an opioid receptor agonist and an opioid receptor antagonist in a de...  
WO/2016/007630A1
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.  
WO/2016/005419A1
The present invention is directed to new compounds of formula (I) selectively binding the cannabinoid 2 receptor. In addition, the invention relates to the use of said compounds for determining cannabinoid receptor 2 (CB2)-selective rece...  
WO/2016/006593A1
Provided are an amyloid fibril formation inhibitor and a therapeutic or prophylactic drug for neurodegenerative diseases, said inhibitor and drug comprising a compound represented by general formula (I), a pharmaceutically acceptable sal...  
WO/2016/007762A1
Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumati...  
WO/2016/005923A1
The disclosure relates to processes for reducing the amount of a compound of formula (I) or a salt or a solvate thereof present in a composition comprising compounds of formulae (I) and (II) or a salt or a solvate thereof.  
WO/2016/007042A3
The invention relates to producing and using 3-methyl-6-(1-methylethenyl)cyclohex-3-ene-1,2-diol epoxides as drugs for the treatment of Parkinson's disease and as antispasmodic drugs and can be used in the field of medicine. The drugs ex...  
WO/2016/004908A1
The new method of preparing 1-(2-(2,4-dimethylphenylsulphanyl)pheny!)piperazine of formula (I) or its salt comprises a reaction of 2-(2,4-dimethylphenylsulphanyl)benzeneamine of formula (XI), wherein Me is methyl, with a suitable precurs...  
WO/2016/007616A1
The present invention provides methods for treating a neurological disorder comprising administering to a patient in need thereof a dose of VX-745, or a pharmaceutically acceptable composition thereof, providing a blood concentration of ...  
WO/2016/004882A1
Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein...  
WO/2016/006947A1
The present invention relates to: a pharmaceutical composition for preventing or treating neurodegenerative diseases, containing a Humulus japonicus extract, which has an inhibitory effect on dopaminergic neuron death, an effect of prote...  
WO/2016/007966A2
Imidazolyl-pyrimidine and related compounds, as can utilize heme-iron coordination in the selective inhibition of neuronal nitric oxide synthase.  
WO/2016/007414A1
The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically...  
WO/2016/007966A3
Imidazolyl-pyrimidine and related compounds, as can utilize heme-iron coordination in the selective inhibition of neuronal nitric oxide synthase.  
WO/2016/004121A1
The invention described herein relates to a cannabis cultivar that produces high concentrations of cannabidiol. The invention further relates to preparations and products derived from the cannabis cultivar. Also provided are methods of t...  
WO/2016/001417A1
The present invention relates to anti- metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.  
WO/2016/003169A3
The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform ...  
WO/2016/004055A1
The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments de...  
WO/2016/000265A1
Disclosed is a use of phthalide compound for the preparation of a medicament. The medicament is especially used for treating and/or delaying the degeneration of Purkinje cells, and the phthalide compound is selected from the following gr...  
WO/2016/003450A1
The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p an...  
WO/2016/003296A1
The invention relates to compounds of general formula (I) wherein: one of A1 and A2 represents a nitrogen atom and the other a carbon atom optionally substituted by halogen; the wave line between the sulfonamido moiety and B/C rings repr...  
WO/2016/002827A1
A therapeutic agent for progressive demyelinating immune disease containing as an effective component thereof an anti-CD27 antibody, an antigen-binding fragment thereof, an anti-CD226 antibody, or an antigen-binding fragment thereof; a t...  
WO/2016/001266A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2016/001398A1
The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropr opoxy)benzylamine hydrochloride.  
WO/2016/002926A1
 An objective of the present invention is to provide a new oxytocin derivative that has a more sustained effect in the body, and a drug composition containing said compound. The objective is met by providing: a new oxytocin derivativ...  
WO/2016/003067A1
The present invention relates to a pharmaceutical composition for suppressing cell transplant rejection, the composition containing a high mobility group box 1 A domain (HMGB1A) as an active ingredient. The use of the composition of the ...  
WO/2016/001390A1
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an...  
WO/2016/003169A2
The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform ...  
WO/2016/002854A1
Provided are: a preparation which can be used for the promotion of the proliferation of neural stem cells, a preparation which can be used for the prevention or treatment of diseases associated with the decrease in neural stem cells, a p...  
WO/2016/002948A1
The purpose of the present invention is to provide a lysophosphatidylserine derivative or salt thereof. The present invention provides a lysophosphatidylserine derivative or salt thereof, and a pharmaceutical composition or lysophosphati...  
WO/2016/001643A1
The present invention relates to dietary supplements, medical foods, or pharmaceutical compositions for use in the enhancement of cognitive function in healthy subjects and/or subjects person suffering from a cognitive deficit, comprisin...  
WO/2016/000361A1
Provided is an application of oxiracetam or levo oxiracetam for preparing a drug preventing or treating neurofunction deficit. Experimental results show that oxiracetam has a noticeable effect as a treatment for ischemic neurofunction de...  
WO/2016/001345A1
The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to ...  
WO/2015/200766A3
The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-...  
WO/2015/200514A3
Provided herein are compounds of the formulas: (I) wherein: n, X2, R3, R3', R4, R4', R5, R5', R6, and R6' are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used...  
WO/2015/200195A1
This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from Sq...  

Matches 651 - 700 out of 112,013